TWI630925B - 用於眼藥物遞送之穩定微脂體調配物 - Google Patents

用於眼藥物遞送之穩定微脂體調配物 Download PDF

Info

Publication number
TWI630925B
TWI630925B TW103111459A TW103111459A TWI630925B TW I630925 B TWI630925 B TW I630925B TW 103111459 A TW103111459 A TW 103111459A TW 103111459 A TW103111459 A TW 103111459A TW I630925 B TWI630925 B TW I630925B
Authority
TW
Taiwan
Prior art keywords
latanoprost
formulation
liposome
popc
drug
Prior art date
Application number
TW103111459A
Other languages
English (en)
Chinese (zh)
Other versions
TW201526924A (zh
Inventor
薩巴拉曼奈恩 凡卡特拉曼
賈亞葛尼斯Ｖ 納塔拉傑
提娜 豪登
法萊迪 波伊
Original Assignee
南洋理工大學
新加坡保健服務私人有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南洋理工大學, 新加坡保健服務私人有限公司 filed Critical 南洋理工大學
Publication of TW201526924A publication Critical patent/TW201526924A/zh
Application granted granted Critical
Publication of TWI630925B publication Critical patent/TWI630925B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW103111459A 2014-01-07 2014-03-27 用於眼藥物遞送之穩定微脂體調配物 TWI630925B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/149,159 2014-01-07
US14/149,159 US9956195B2 (en) 2014-01-07 2014-01-07 Stable liposomal formulations for ocular drug delivery

Publications (2)

Publication Number Publication Date
TW201526924A TW201526924A (zh) 2015-07-16
TWI630925B true TWI630925B (zh) 2018-08-01

Family

ID=50112787

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103111459A TWI630925B (zh) 2014-01-07 2014-03-27 用於眼藥物遞送之穩定微脂體調配物

Country Status (9)

Country Link
US (1) US9956195B2 (es)
EP (1) EP2891484B1 (es)
JP (1) JP6463902B2 (es)
KR (1) KR102315264B1 (es)
CN (1) CN104758249B (es)
ES (1) ES2676213T3 (es)
HK (1) HK1206254A1 (es)
TW (1) TWI630925B (es)
WO (1) WO2015105458A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2892564A4 (en) * 2012-09-06 2016-04-27 Univ Nanyang Tech HYALURONIC ACID MEDICINE DELIVERY SYSTEMS
EP3445335A4 (en) * 2016-04-19 2020-03-04 Nanyang Technological University FORMULATIONS FORMING A SUB-CONJUNCTIVAL DEPOSIT FOR THE ADMINISTRATION OF MEDICATION AT THE EYE LEVEL
US11452703B2 (en) 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011098578A2 (en) * 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
US20130216606A1 (en) * 2010-08-12 2013-08-22 Singapore Health Services Pte Ltd Liposomal formulation for ocular drug delivery

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU617678B2 (en) 1987-05-22 1991-12-05 Liposome Company, Inc., The Prostaglandin-lipid formulations
US5925375A (en) 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
US4938965A (en) 1987-07-22 1990-07-03 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Ocular delivery of prophylactic agents
SE8703854D0 (sv) 1987-10-07 1987-10-07 Pharmacia Ab Prostaglandinderivat for behandling av glaukom eller okuler hypertension
JP2602964B2 (ja) 1989-10-16 1997-04-23 裕 水島 プロスタグランジン類縁体およびその脂肪乳剤
US5478819A (en) 1993-06-23 1995-12-26 Simo Tarpila Phospholipid composition and use thereof
US6773719B2 (en) 1994-03-04 2004-08-10 Esperion Luv Development, Inc. Liposomal compositions, and methods of using liposomal compositions to treat dislipidemias
AU2230497A (en) 1996-02-26 1997-09-10 Daiichi Pharmaceutical Co., Ltd. Liposome and liposome dispersion
US6015716A (en) * 1996-07-12 2000-01-18 The Liposome Company, Inc. Detection of endotoxin levels in liposomes, lipid bilayers and lipid complexes
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1998043616A1 (en) 1997-03-31 1998-10-08 University Of Iowa Research Foundation Glycosylceramide-containing liposomes
JP2003517441A (ja) 1998-09-25 2003-05-27 アルコン ラボラトリーズ， インコーポレイテッド 徐放性で快適な眼疾病用組成物および眼疾病の治療方法
US20030068365A1 (en) 2001-10-05 2003-04-10 Pichit Suvanprakorn Compositions and methods for administration of active agents using liposome beads
EP1487872A1 (en) 2002-03-27 2004-12-22 Theratechnologies Inc. Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions
KR101027454B1 (ko) 2002-08-23 2011-04-06 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 안정한 점안액
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
AU2003297607A1 (en) 2002-12-02 2004-06-23 Genvec, Inc Materials and methods for treating ocular-related disorders
WO2004058289A1 (en) 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060165744A1 (en) 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations
US20050054723A1 (en) 2003-05-27 2005-03-10 Johan Stjernschantz Method for the treatment of glaucoma and ocular hypertension with prostaglandin analogues without melanogenic side effect
EP1667705A1 (en) 2003-10-03 2006-06-14 Allergan, Inc. Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia
WO2005094790A1 (es) 2004-04-02 2005-10-13 Italfarmaco, S.A. Formulaciones liposomales
US8722097B2 (en) * 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
EP1759702B1 (en) 2004-05-26 2009-01-07 Arturo Jimenez Bayardo Method of preparing a latanoprost ophthalmic solution and solution thus produced
BRPI0511807C8 (pt) 2004-06-04 2021-05-25 Camurus Ab pré-formulação, processo de formação de uma pré-formulação e uso da mesma
AU2005276245C1 (en) 2004-08-23 2015-02-26 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated introacular pressure by siRNAs
BRPI0514835A (pt) * 2004-09-03 2008-06-24 Creabilis Therapeutics Spa variante de polipetìdeo de box de domìnio de ligação por alta afinidade de hmbg1 humano e/ou não humano ou de fragmento biologicamente ativo de box-a de hmgb1, molécula de ácido nucléico, uso, composição farmacêutica e dispositivo médico
HUE028833T2 (en) 2004-09-09 2017-01-30 Yeda Res & Dev Polypeptide mixtures, compositions containing them, process for their preparation, and applications
ES2314354T3 (es) 2004-11-09 2009-03-16 Novagali Pharma S.A. Emulsion de tipo aceite en agua con baja concentracion de agente cationico y potencial zeta positivo.
US20060188481A1 (en) 2005-02-22 2006-08-24 Saitama Medical School Methods for prophylactically or therapeutically treating an animal for an ocular-related disorder
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
PT1864666E (pt) 2005-03-31 2012-09-06 Santen Pharmaceutical Co Ltd Agente protector para célula neuronal retiniana contendo derivado de prostaglandina f2 alfa como ingrediente activo
US20070026061A1 (en) 2005-05-25 2007-02-01 Nahid Ali Liposomal formulation and use thereof
US9539202B2 (en) 2006-04-28 2017-01-10 Universidad Complutense De Madrid Formulation of liposomal vesicles in aqueous solutions with lachrymal film characteristics
WO2008120249A1 (en) 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
CN101049504B (zh) * 2007-04-05 2010-05-19 广州立恩生物科技有限公司 一种脂质体药物载体及其制备方法
EP1985298A1 (en) 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
WO2009025763A2 (en) 2007-08-16 2009-02-26 Schepens Eye Research Institute Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
IL186598A0 (en) * 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
KR20150115959A (ko) 2007-10-12 2015-10-14 레솔빅스 파마슈티칼즈, 인코퍼레이티드 안과 질환의 치료를 위한 옥실리핀 화합물
WO2009107753A1 (ja) 2008-02-29 2009-09-03 財団法人 名古屋産業科学研究所 後眼部到達用リポソーム及び後眼部疾患用医薬組成物
ITRM20080182A1 (it) 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
JP2011520805A (ja) 2008-05-09 2011-07-21 キューエルティー プラグ デリバリー，インク． 緑内障および高眼圧症治療のための活性剤の持続送達
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
JP2011525388A (ja) 2008-06-24 2011-09-22 キューエルティー プラグ デリバリー，インク． 緑内障の併用治療
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
RU2011134043A (ru) 2009-01-23 2013-02-20 Клт Инк. Доставка одного или более агента с продолжительным высвобождением
CA2750242C (en) 2009-02-12 2018-05-22 Incept, Llc Drug delivery through hydrogel plugs
US20100247606A1 (en) 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
EP3175862A1 (en) 2009-08-24 2017-06-07 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
EP2478906A4 (en) 2009-09-17 2013-02-20 Senju Pharma Co AQUEOUS OPHTHALMIC DROPS THAT CONTAIN LATANOPROST, AND A METHOD OF INHIBITING ADSORPTION OF LATANOPROST ON A RESIN
US20110070294A1 (en) 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
EP3569223A1 (en) 2009-10-30 2019-11-20 Intratus, Inc. Methods and compositions for sustained delivery of drugs
US8889193B2 (en) 2010-02-25 2014-11-18 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
US20110294730A1 (en) 2010-05-31 2011-12-01 Shantha Totada R Method of treating glaucoma and intraocular hypertension
WO2012063237A2 (en) 2010-11-08 2012-05-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
JP6023082B2 (ja) 2011-01-24 2016-11-09 インセプタム リサーチ アンド セラピューティクス，インク． 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物
EP3290024B1 (en) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
US9248135B2 (en) 2012-04-24 2016-02-02 Allergan, Inc. Prostaglandin and vasoconstrictor pharmaceutical compositions and methods of use
WO2013164671A1 (en) 2012-05-03 2013-11-07 Qlt Inc. Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP2892564A4 (en) 2012-09-06 2016-04-27 Univ Nanyang Tech HYALURONIC ACID MEDICINE DELIVERY SYSTEMS
CN104884006B (zh) 2012-10-26 2017-12-15 弗赛特影像5股份有限公司 用于持续释放药物到眼睛的眼科系统
US9283231B2 (en) 2013-01-31 2016-03-15 Icon Bioscience, Inc. Sustained release formulations for the treatment of intraocular pressure of glaucoma
CN105431138B (zh) 2013-03-27 2019-01-11 全球药物科技有限公司 眼药组合物、其制备方法及用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011098578A2 (en) * 2010-02-12 2011-08-18 Bioneer A/S Liposome system for ocular administration
US20130216606A1 (en) * 2010-08-12 2013-08-22 Singapore Health Services Pte Ltd Liposomal formulation for ocular drug delivery

Also Published As

Publication number Publication date
TW201526924A (zh) 2015-07-16
ES2676213T3 (es) 2018-07-17
HK1206254A1 (en) 2016-01-08
CN104758249A (zh) 2015-07-08
KR102315264B1 (ko) 2021-10-20
EP2891484A1 (en) 2015-07-08
JP2015129107A (ja) 2015-07-16
US20150190359A1 (en) 2015-07-09
US9956195B2 (en) 2018-05-01
EP2891484B1 (en) 2018-04-11
WO2015105458A1 (en) 2015-07-16
KR20150082078A (ko) 2015-07-15
CN104758249B (zh) 2019-08-23
JP6463902B2 (ja) 2019-02-06

Similar Documents

Publication Publication Date Title
EP2262476B1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
JP2019518730A (ja) 眼の炎症性障害および疾患の組合せ処置
US11826467B2 (en) W/O/W microemulsions for ocular administration
KR20110129869A (ko) 하나 이상의 제제의 서방형 전달
CA2846384A1 (en) Sustained release delivery of active agents to treat glaucoma and ocular hypertension
JP6924429B2 (ja) 眼科用薬物の定量的な眼窩周囲への適用
TWI630925B (zh) 用於眼藥物遞送之穩定微脂體調配物
JP2021518352A (ja) チモロールを含む医薬組成物
WO2019024433A1 (zh) 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用
US9636347B2 (en) Sustained release formulations for the treatment of intraocular pressure or glaucoma
Shimazawa et al. Topical diclofenac-loaded liposomes ameliorate laser-induced choroidal neovascularization in mice and non-human primates
WO2018011705A1 (en) Liposome-based eye drops and use thereof for in vivo evaluation of the drug efficacy of medical and surgical anti-glaucoma therapy
WO2013164671A1 (en) Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
Law et al. Ocular pharmacology
Chauhan et al. Management of glaucoma: effective drug delivery via Niosomes
US20240285572A1 (en) Compositions comprising nitric oxide-releasing compounds for treating choroidal vascular diseases and methods of their use
KR20230147006A (ko) 무방부제 안과용 약학 에멀젼 및 이의 적용
Garrigue et al. A comparative study of latanoprost-cationic emulsion (Catioprost) and latanoprost aqueous solution (Xalatan) in preclinical efficacy and safety models
Sahoo et al. Mucoadhesive nanopolymers for posterior segment drug delivery
US20230064711A1 (en) Compositions, kits and methods for enhancing therapeutic compliance
PAUL et al. International Journal of Pharmacy and Pharmaceutical Sciences
TR201612001A1 (tr) Anti̇glokom akti̇vi̇teye sahi̇p oftalmi̇k formülasyonlar
TR201606768A1 (tr) Oftalmi̇k farmasöti̇k terki̇pler